Table 7 Incidence and incidence rates of primary, secondary, and tertiary end points
|  | Linagliptin (n = 5847) | Total comparators (n = 3612) | ||
|---|---|---|---|---|
| Â | Incidence n (%) | Incidence rate (per 1000Â years) | Incidence n (%) | Incidence rate (per 1000Â years) |
Primary end points | Â | Â | Â | Â |
CV death, stroke, MI, or UAP with hospitalization | 60 (1.0) | 13.4 | 62 (1.7) | 18.9 |
Secondary end points | Â | Â | Â | Â |
CV death, stroke, or MI | 42 (0.7) | 9.3 | 46 (1.3) | 14.0 |
All major CV events | 96 (1.6) | 21.5 | 95 (2.6) | 29.1 |
FDA-custom MACE | 39 (0.7) | 8.7 | 45 (1.3) | 13.7 |
Tertiary end points | Â | Â | Â | Â |
CV death | 11 (0.2) | 2.4 | 8 (0.2) | 2.4 |
Non-fatal MI | 23 (0.4) | 5.1 | 20 (0.6) | 6.1 |
Non-fatal stroke | 9 (0.2) | 2.0 | 19 (0.5) | 5.8 |
TIA | 1 (0.02) | 0.2 | 8 (0.2) | 2.4 |
UAP with hospitalization | 22 (0.4) | 4.9 | 16 (0.4) | 4.8 |
Hospitalization for CHF* | 12 (0.6) | 8.8 | 9 (0.7) | 8.4 |
Total mortality | 18 (0.3) | 4.0 | 16 (0.4) | 4.8 |